Literature DB >> 22438779

Anesthetic management for Wingspan stent.

Ehab Farag1, Alaa Abd-Elsayed, Michael Anderson, Joseph Abdelmalak, Armin Schubert.   

Abstract

BACKGROUND: The bare metal self-expanding Wingspan stent (Boston Scientific, Natick, MA) was approved by the Food and Drug Administration under the Humanitarian Device Exemption in August 2005 for patients with intracranial atherosclerotic disease (ICAD) who are refractory to medical therapy. Relatively low rates of periprocedural morbidity and mortality have been reported.
METHODS: After receiving institutional review board approval, we conducted a retrospective chart review to examine the anesthetic management and perioperative mortality and morbidity for all Wingspan stent insertions performed at our institution from 2005 to 2007.
RESULTS: A total of 72 patients with a history of intracranial stenosis had angioplasty and Wingspan stent insertion: 34 male and 38 female, with an average age of 64 ± 11.6 years. Preoperative systolic blood pressure was 200 ± 45 mmHg, and diastolic blood pressure was 100 ± 23 mmHg. All patients received general anesthesia for stent insertion. Five patients died (6.9%), 4 had perioperative stroke (5.5%), and 9 had recurrent stenosis (12.5%).
CONCLUSIONS: Anesthetic management for Wingspan stent insertion for ICAD is challenging. Maintenance of hemodynamic stability with optimum brain perfusion during the stent deployment is crucial to patient safety. A prospective study is warranted to assess the optimal anesthetic choice during Wingspan stent insertion.

Entities:  

Keywords:  Anesthetic management; Wingspan stent; bare metal; intracranial atherosclerosis; self-expanding; stent

Year:  2012        PMID: 22438779      PMCID: PMC3307502     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  17 in total

1.  Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.

Authors:  Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

2.  Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats.

Authors:  Kristin Engelhard; Christian Werner; Susanne Kaspar; Oliver Möllenberg; Manfred Blobner; Monika Bachl; Eberhard Kochs
Journal:  Anesthesiology       Date:  2002-02       Impact factor: 7.892

3.  Dexmedetomidine does not increase the incidence of intracarotid shunting in patients undergoing awake carotid endarterectomy.

Authors:  Alex Bekker; Mark Gold; Raza Ahmed; Jung Kim; Caron Rockman; Glenn Jacobovitz; Thomas Riles; Gene Fisch
Journal:  Anesth Analg       Date:  2006-10       Impact factor: 5.108

4.  US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results.

Authors:  David Fiorella; Elad I Levy; Aquilla S Turk; Felipe C Albuquerque; David B Niemann; Beverly Aagaard-Kienitz; Ricardo A Hanel; Henry Woo; Peter A Rasmussen; L Nelson Hopkins; Thomas J Masaryk; Cameron G McDougall
Journal:  Stroke       Date:  2007-02-08       Impact factor: 7.914

5.  Further proof that the spinal cord, and not the brain, mediates the immobility produced by inhaled anesthetics.

Authors:  Jing Yang; Yun-Fei Chai; Chun-Yu Gong; Guo-hua Li; Nan Luo; Nan-Fu Luo; Jin Liu
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

6.  Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent.

Authors:  Krisztian J Kapinya; Diana Löwl; Carsten Fütterer; Martin Maurer; Klaus F Waschke; Nikolaj K Isaev; Ulrich Dirnagl
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

7.  Dexmedetomidine decreases cerebral blood flow velocity in humans.

Authors:  M H Zornow; M Maze; J B Dyck; S L Shafer
Journal:  J Cereb Blood Flow Metab       Date:  1993-03       Impact factor: 6.200

8.  Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: role of beta 1- and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II.

Authors:  Markus Lange; Andreas Redel; Christopher Lotz; Thorsten M Smul; Christoph Blomeyer; Anja Frank; Jan Stumpner; Norbert Roewer; Franz Kehl
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

Review 9.  Nicardipine: applications in anesthesia practice.

Authors:  J D Tobias
Journal:  J Clin Anesth       Date:  1995-09       Impact factor: 9.452

10.  Effect of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs.

Authors:  B R Karlsson; M Forsman; O K Roald; M S Heier; P A Steen
Journal:  Anesth Analg       Date:  1990-08       Impact factor: 5.108

View more
  1 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.